Study on the Use of Sarilumab in Patients With COVID-19 Infection
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Sarilumab is an anti-interleukin-6 human monoclonal antibody, such as tocilizumab, which is
administered subcutaneously every two weeks for the treatment of moderate to severe active
rheumatoid arthritis in adult patients. Despite the effectiveness reported for tocilizumab in
the recently published experiences, the need to rapidly find alternative therapies to manage
the complications of Covid-19 infection remains extremely high. The lack of clinical
experience on the usage of sarilumab in such patients prevents the possibility of adopting
early access programs for using commercially available sarilumab (prefilled syringe) packs in
patients with severe Covid-19 pneumonia. The present study is aimed to generate a rapid,
still robustly documented, evidence on the potential clinical efficacy and tolerability of a
further IL-6R antagonist in Covid-19 pneumonia.